{"id":2150,"date":"2025-12-11T03:59:42","date_gmt":"2025-12-11T03:59:42","guid":{"rendered":"https:\/\/subject157.com\/?p=2150"},"modified":"2026-01-23T16:40:35","modified_gmt":"2026-01-23T16:40:35","slug":"tesamorelin-evidencia-humana-vat-igf1","status":"publish","type":"post","link":"https:\/\/subject157.com\/it\/modulazione-dellasse-gh-igf-1-e-riduzione-del-grasso-viscerale-con-tesamorelina-revisione-degli-studi-clinici-e-implicazioni-metaboliche-2025\/","title":{"rendered":"Modulazione dell'asse GH\/IGF-1 e riduzione del grasso viscerale con la tesamorelina: revisione degli studi clinici e delle implicazioni metaboliche (2025)"},"content":{"rendered":"<!-- =========================================================\nSUBJECT 157 \u2014 JOURNAL POST (HTML pronto a colar)\nT\u00edtulo (WP): Tesamorelin (TH9507): Evid\u00eancia humana, gordura visceral (VAT) e IGF-1 \u2014 leitura operacional (2007\u20132024)\nSubtitle (Custom Field): subject157_subtitle = Um mapa audit\u00e1vel do que a evid\u00eancia humana realmente mostra (VAT, IGF-1, metabolismo) + gr\u00e1ficos, red flags e links internos S157.\nSlug (recomendado): tesamorelin-evidencia-humana-vat-igf1\n========================================================= -->\n\n<h2 class=\"wp-block-heading\">Astratto<\/h2>\n\n<p>\n  O <strong>Tesamorelina<\/strong> (TH9507) \u00e9 um an\u00e1logo de <strong>GHRH<\/strong> (um \u201csinal\u201d que manda a hip\u00f3fise libertar GH). Em estudos humanos controlados, o resultado mais consistente \u00e9:\n  <strong>redu\u00e7\u00e3o de gordura visceral<\/strong> (<strong>VAT<\/strong>, a gordura mais \u201cprofunda\u201d, \u00e0 volta dos \u00f3rg\u00e3os) ao longo de ~26 semanas, com um efeito paralelo esperado:\n  <strong>IGF-1 no sangue sobe<\/strong> (um ponto de <strong>monitoriza\u00e7\u00e3o<\/strong>, n\u00e3o um \u201ctrof\u00e9u\u201d).\n  Este artigo pega na literatura e traduz para leitura operacional S157: o que \u00e9 s\u00f3lido, o que varia, como ler VAT vs marcadores no sangue e onde est\u00e3o as <strong>bandiere rosse<\/strong> (m\u00e9todo, medi\u00e7\u00e3o e interpreta\u00e7\u00e3o).\n<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<div class=\"subject157-note\">\n  <strong>Atalhos (navega\u00e7\u00e3o r\u00e1pida)<\/strong><br>\n  <a href=\"#s157-core\">1) O que \u00e9 (GHRH \u2192 GH\/IGF-1)<\/a> -\n  <a href=\"#s157-evidence\">2) O que os estudos humanos mostram (VAT\/IGF-1)<\/a> -\n  <a href=\"#s157-graphs\">3) Gr\u00e1ficos + tabela (audit\u00e1veis)<\/a> -\n  <a href=\"#s157-timing\">4) Timing (meia-vida vs dura\u00e7\u00e3o)<\/a> -\n  <a href=\"#s157-safety\">5) Seguran\u00e7a e monitoriza\u00e7\u00e3o<\/a> -\n  <a href=\"#s157-framework\">6) Mini-framework S157<\/a> -\n  <a href=\"#s157-related\">Profili di database correlati<\/a> -\n  <a href=\"#s157-refs\">Riferimenti<\/a>\n<\/div>\n\n<div class=\"subject157-note\">\n  <strong>Strumenti di validazione (S157)<\/strong><br>\n  Antes de interpretares \u201cefeito\u201d, elimina falsos sinais operacionais:\n  <ul style=\"margin:10px 0 0 18px;\">\n    <li><a href=\"https:\/\/subject157.com\/it\/strumenti-di-laboratorio\/\"><strong>Strumenti di laboratorio<\/strong><\/a> \u2014 consist\u00eancia do processo (reconstitui\u00e7\u00e3o, concentra\u00e7\u00e3o, registo).<\/li>\n    <li><a href=\"https:\/\/subject157.com\/it\/calcolatrice-u-100\/\"><strong>Calcolatrice U-100<\/strong><\/a> \u2014 leitura de escala e preven\u00e7\u00e3o de erros Type A\/B.<\/li>\n    <li><a href=\"https:\/\/subject157.com\/it\/revisore-dei-conti-coa\/\"><strong>Revisore COA<\/strong><\/a> \u2014 rastreabilidade, lote, m\u00e9todo e auditoria estruturada.<\/li>\n  <\/ul>\n<\/div>\n\n<h2 class=\"wp-block-heading\" id=\"s157-core\">1) Conceito-n\u00facleo: o que o Tesamorelin faz (sem exageros)<\/h2>\n\n<p>\n  <strong>Tesamorelina<\/strong> \u00e9 um <strong>an\u00e1logo de GHRH<\/strong>. Em linguagem simples: ele \u201cpuxa o gatilho\u201d do eixo normal para libertar <strong>GH<\/strong> e, por consequ\u00eancia, subir <strong>IGF-1<\/strong>.\n  Isto interessa por duas raz\u00f5es pr\u00e1ticas:\n<\/p>\n\n<ul class=\"wp-block-list\">\n  <li><strong>Forma do sinal:<\/strong> trabalha via eixo end\u00f3geno (tende a respeitar l\u00f3gica de <em>pulsos<\/em>), em vez de \u201cfor\u00e7ar\u201d um n\u00edvel basal constante.<\/li>\n  <li><strong>Resultado humano mais repetido:<\/strong> <strong>VAT \u2193<\/strong> (gordura visceral medida por imagem) em ensaios controlados.<\/li>\n<\/ul>\n\n<p>\n  Termos r\u00e1pidos:\n  <strong>VAT<\/strong> = gordura visceral (mais profunda, \u00e0 volta dos \u00f3rg\u00e3os). N\u00e3o \u00e9 o mesmo que gordura subcut\u00e2nea (a que \u201cv\u00eas\u201d por fora).\n  Para defini\u00e7\u00f5es (GHRH, GH, IGF-1, VAT, puls\u00e1til vs cont\u00ednuo), usa o\n  <a href=\"https:\/\/subject157.com\/it\/s157-lessico-tattico-glossario\/\"><strong>S157 Lessico<\/strong><\/a> (procura \u201cGHRH\u201d, \u201cIGF-1\u201d, \u201cVAT\u201d).\n<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-evidence\">2) Evid\u00eancia humana: o que \u00e9 consistente (e o que costuma variar)<\/h2>\n\n<p>\n  Em ensaios cl\u00ednicos (contexto m\u00e9dico espec\u00edfico), a fotografia geral \u00e9 consistente:\n  <strong>VAT reduz<\/strong> ao fim de ~26 semanas no bra\u00e7o Tesamorelin, e <strong>IGF-1 sobe<\/strong>.\n  J\u00e1 \u201cmetab\u00f3lico\u201d (glicemia, l\u00edpidos, inflama\u00e7\u00e3o) aparece com resultados mais <em>mistos<\/em> porque depende muito de:\n  <strong>quem<\/strong> foi estudado, <strong>o que<\/strong> foi medido e <strong>como<\/strong> foi medido.\n<\/p>\n\n<table style=\"width:100%; border-collapse:separate; border-spacing:0; overflow:hidden; border:1px solid rgba(15,23,42,0.10); border-radius:16px; background:#FFFFFF;\">\n  <thead>\n    <tr>\n      <th style=\"text-align:left; padding:12px 14px; background:#F8FAFC; border-bottom:1px solid rgba(15,23,42,0.10);\">Bloco<\/th>\n      <th style=\"text-align:left; padding:12px 14px; background:#F8FAFC; border-bottom:1px solid rgba(15,23,42,0.10);\">O que tende a repetir<\/th>\n      <th style=\"text-align:left; padding:12px 14px; background:#F8FAFC; border-bottom:1px solid rgba(15,23,42,0.10);\">Onde nasce \u201cbarulho\u201d<\/th>\n    <\/tr>\n  <\/thead>\n  <tbody>\n    <tr>\n      <td style=\"padding:12px 14px; border-bottom:1px solid rgba(15,23,42,0.06);\"><strong>VAT (imagem)<\/strong><\/td>\n      <td style=\"padding:12px 14px; border-bottom:1px solid rgba(15,23,42,0.06); color:#334155;\"><strong>VAT \u2193<\/strong> \u00e9 o resultado humano mais consistente quando medido por CT\/MRI.<\/td>\n      <td style=\"padding:12px 14px; border-bottom:1px solid rgba(15,23,42,0.06); color:#334155;\">M\u00e9todo (CT vs estimativa), baseline, ades\u00e3o e comparabilidade entre estudos.<\/td>\n    <\/tr>\n    <tr>\n      <td style=\"padding:12px 14px; border-bottom:1px solid rgba(15,23,42,0.06);\"><strong>IGF-1 (sangue)<\/strong><\/td>\n      <td style=\"padding:12px 14px; border-bottom:1px solid rgba(15,23,42,0.06); color:#334155;\"><strong>IGF-1 \u2191<\/strong> \u00e9 esperado; \u00e9 um <strong>ponto de controlo<\/strong> (monitorizar).<\/td>\n      <td style=\"padding:12px 14px; border-bottom:1px solid rgba(15,23,42,0.06); color:#334155;\">Timing de colheita, idade, varia\u00e7\u00e3o laboratorial e leitura fora de contexto.<\/td>\n    <\/tr>\n    <tr>\n      <td style=\"padding:12px 14px;\"><strong>Metabolico<\/strong><\/td>\n      <td style=\"padding:12px 14px; color:#334155;\">Pode haver mudan\u00e7as moderadas em alguns marcadores (depende do endpoint).<\/td>\n      <td style=\"padding:12px 14px; color:#334155;\">Endpoint errado, janela curta, confus\u00e3o \u201cmarcador vs resultado\u201d, e erros operacionais.<\/td>\n    <\/tr>\n  <\/tbody>\n<\/table>\n\n<p style=\"margin-top:10px; color:#64748b; font-size:13px; line-height:1.6;\">\n  Nota S157: \u201crepete\u201d n\u00e3o significa \u201cgarante\u201d. Significa que aparece v\u00e1rias vezes quando o desenho \u00e9 controlado e a medi\u00e7\u00e3o \u00e9 s\u00f3lida.\n<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-graphs\">3) Gr\u00e1ficos + tabela (audit\u00e1veis): VAT e IGF-1 a ~26 semanas<\/h2>\n\n<p>\n  Abaixo tens um resumo <strong>visual<\/strong> (gr\u00e1ficos) e um resumo <strong>num\u00e9rico<\/strong> (tabela) com os dados de 26 semanas dos ensaios cl\u00ednicos descritos na documenta\u00e7\u00e3o p\u00fablica.\n  N\u00e3o \u00e9 meta-an\u00e1lise e n\u00e3o \u201cpromete\u201d efeito individual \u2014 serve para <strong>ler a forma do sinal<\/strong> e evitar interpreta\u00e7\u00f5es erradas.\n<\/p>\n\n<div style=\"border:1px solid rgba(15,23,42,0.10); border-radius:16px; background:#FFFFFF; padding:14px; margin:12px 0;\">\n  <div style=\"font-weight:900; color:#0f172a; margin-bottom:6px;\">Tabela \u2014 26 semanas (m\u00e9dia): VAT (%) e IGF-1 (ng\/mL)<\/div>\n  <div style=\"color:#64748b; font-size:13px; line-height:1.55; margin-bottom:10px;\">\n    Leitura r\u00e1pida: <strong>VAT desce<\/strong> no Tesamorelin e muda pouco no placebo. <strong>IGF-1 sobe<\/strong> no Tesamorelin (monitoriza\u00e7\u00e3o relevante).\n  <\/div>\n\n  <table style=\"width:100%; border-collapse:separate; border-spacing:0; overflow:hidden; border:1px solid rgba(15,23,42,0.08); border-radius:14px;\">\n    <thead>\n      <tr>\n        <th style=\"text-align:left; padding:10px 12px; background:#F8FAFC; border-bottom:1px solid rgba(15,23,42,0.08);\">Estudo<\/th>\n        <th style=\"text-align:left; padding:10px 12px; background:#F8FAFC; border-bottom:1px solid rgba(15,23,42,0.08);\">VAT (% mudan\u00e7a)<\/th>\n        <th style=\"text-align:left; padding:10px 12px; background:#F8FAFC; border-bottom:1px solid rgba(15,23,42,0.08);\">IGF-1 (ng\/mL mudan\u00e7a)<\/th>\n      <\/tr>\n    <\/thead>\n    <tbody>\n      <tr>\n        <td style=\"padding:10px 12px; border-bottom:1px solid rgba(15,23,42,0.06);\"><strong>Study 1<\/strong><\/td>\n        <td style=\"padding:10px 12px; border-bottom:1px solid rgba(15,23,42,0.06); color:#334155;\">\n          Tesamorelin: <strong>-18%<\/strong> \u00b7 Placebo: <strong>+2%<\/strong>\n        <\/td>\n        <td style=\"padding:10px 12px; border-bottom:1px solid rgba(15,23,42,0.06); color:#334155;\">\n          Tesamorelin: <strong>+107<\/strong> \u00b7 Placebo: <strong>-15<\/strong>\n        <\/td>\n      <\/tr>\n      <tr>\n        <td style=\"padding:10px 12px;\"><strong>Study 2<\/strong><\/td>\n        <td style=\"padding:10px 12px; color:#334155;\">\n          Tesamorelin: <strong>-14%<\/strong> \u00b7 Placebo: <strong>-2%<\/strong>\n        <\/td>\n        <td style=\"padding:10px 12px; color:#334155;\">\n          Tesamorelin: <strong>+108<\/strong> \u00b7 Placebo: <strong>+3<\/strong>\n        <\/td>\n      <\/tr>\n    <\/tbody>\n  <\/table>\n\n  <p style=\"margin-top:10px; color:#64748b; font-size:13px; line-height:1.6;\">\n    Nota: n\u00fameros acima s\u00e3o m\u00e9dias a ~26 semanas conforme descrito em documenta\u00e7\u00e3o p\u00fablica (ver \u201cRefer\u00eancias\u201d).\n  <\/p>\n<\/div>\n\n<div style=\"display:grid; grid-template-columns:1fr; gap:14px; margin:12px 0;\">\n  <div style=\"border:1px solid rgba(15,23,42,0.10); border-radius:16px; background:#FFFFFF; padding:14px;\">\n    <div style=\"font-weight:900; color:#0f172a; margin-bottom:6px;\">Gr\u00e1fico 1 \u2014 Mudan\u00e7a em VAT (%), ~26 semanas (Tesamorelin vs Placebo)<\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55; margin-bottom:10px;\">\n      Leitura: valores negativos = <strong>menos gordura visceral<\/strong>. Cada \u201cStudy\u201d corresponde a um ensaio descrito em documenta\u00e7\u00e3o p\u00fablica.\n    <\/div>\n\n    <svg viewbox=\"0 0 820 280\" width=\"100%\" height=\"auto\" role=\"img\" aria-label=\"Mudan\u00e7a em VAT percentual a 26 semanas\">\n      <line x1=\"60\" y1=\"30\" x2=\"60\" y2=\"240\" stroke=\"#94A3B8\" stroke-width=\"2\"\/>\n      <line x1=\"60\" y1=\"240\" x2=\"790\" y2=\"240\" stroke=\"#94A3B8\" stroke-width=\"2\"\/>\n\n      <g fill=\"#64748B\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">\n        <text x=\"18\" y=\"58\">+5<\/text>\n        <text x=\"26\" y=\"90\">0<\/text>\n        <text x=\"20\" y=\"122\">-5<\/text>\n        <text x=\"12\" y=\"154\">-10<\/text>\n        <text x=\"12\" y=\"186\">-15<\/text>\n        <text x=\"12\" y=\"218\">-20<\/text>\n      <\/g>\n      <g stroke=\"#E2E8F0\" stroke-width=\"1\">\n        <line x1=\"60\" y1=\"82\" x2=\"790\" y2=\"82\"\/>\n        <line x1=\"60\" y1=\"114\" x2=\"790\" y2=\"114\"\/>\n        <line x1=\"60\" y1=\"146\" x2=\"790\" y2=\"146\"\/>\n        <line x1=\"60\" y1=\"178\" x2=\"790\" y2=\"178\"\/>\n        <line x1=\"60\" y1=\"210\" x2=\"790\" y2=\"210\"\/>\n      <\/g>\n\n      <!-- Study 1 -->\n      <g>\n        <text x=\"150\" y=\"265\" fill=\"#0f172a\" font-size=\"13\" font-family=\"Inter, system-ui, sans-serif\" font-weight=\"800\">Study 1<\/text>\n        <rect x=\"120\" y=\"82\" width=\"70\" height=\"144\" fill=\"rgba(0,214,160,0.35)\" stroke=\"rgba(0,214,160,0.9)\"\/>\n        <text x=\"124\" y=\"74\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Tesa: -18%<\/text>\n\n        <rect x=\"200\" y=\"70\" width=\"70\" height=\"12\" fill=\"rgba(148,163,184,0.35)\" stroke=\"rgba(148,163,184,0.9)\"\/>\n        <text x=\"204\" y=\"64\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Plac: +2%<\/text>\n      <\/g>\n\n      <!-- Study 2 -->\n      <g>\n        <text x=\"430\" y=\"265\" fill=\"#0f172a\" font-size=\"13\" font-family=\"Inter, system-ui, sans-serif\" font-weight=\"800\">Study 2<\/text>\n        <rect x=\"400\" y=\"82\" width=\"70\" height=\"112\" fill=\"rgba(0,214,160,0.35)\" stroke=\"rgba(0,214,160,0.9)\"\/>\n        <text x=\"404\" y=\"74\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Tesa: -14%<\/text>\n\n        <rect x=\"480\" y=\"82\" width=\"70\" height=\"16\" fill=\"rgba(148,163,184,0.35)\" stroke=\"rgba(148,163,184,0.9)\"\/>\n        <text x=\"484\" y=\"74\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Plac: -2%<\/text>\n      <\/g>\n\n      <g font-family=\"Inter, system-ui, sans-serif\" font-size=\"12\" fill=\"#334155\">\n        <rect x=\"610\" y=\"36\" width=\"14\" height=\"14\" fill=\"rgba(0,214,160,0.35)\" stroke=\"rgba(0,214,160,0.9)\"\/>\n        <text x=\"632\" y=\"48\">Tesamorelina<\/text>\n        <rect x=\"610\" y=\"58\" width=\"14\" height=\"14\" fill=\"rgba(148,163,184,0.35)\" stroke=\"rgba(148,163,184,0.9)\"\/>\n        <text x=\"632\" y=\"70\">Placebo<\/text>\n      <\/g>\n    <\/svg>\n\n    <div style=\"margin-top:10px; color:#64748b; font-size:13px; line-height:1.6;\">\n      Nota: aqui mostramos <strong>% mudan\u00e7a em VAT<\/strong> a ~26 semanas. VAT \u00e9 medido por imagem (CT\/MRI) em contexto cl\u00ednico.\n    <\/div>\n  <\/div>\n\n  <div style=\"border:1px solid rgba(15,23,42,0.10); border-radius:16px; background:#FFFFFF; padding:14px;\">\n    <div style=\"font-weight:900; color:#0f172a; margin-bottom:6px;\">Gr\u00e1fico 2 \u2014 Mudan\u00e7a em IGF-1 (ng\/mL), ~26 semanas (Tesamorelin vs Placebo)<\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55; margin-bottom:10px;\">\n      Leitura: IGF-1 tende a subir no bra\u00e7o Tesamorelin. Isto \u00e9 um ponto de <strong>monitoriza\u00e7\u00e3o<\/strong> (contexto m\u00e9dico).\n    <\/div>\n\n    <svg viewbox=\"0 0 820 300\" width=\"100%\" height=\"auto\" role=\"img\" aria-label=\"Mudan\u00e7a em IGF-1 em ng\/mL a 26 semanas\">\n      <line x1=\"60\" y1=\"30\" x2=\"60\" y2=\"255\" stroke=\"#94A3B8\" stroke-width=\"2\"\/>\n      <line x1=\"60\" y1=\"255\" x2=\"790\" y2=\"255\" stroke=\"#94A3B8\" stroke-width=\"2\"\/>\n\n      <!-- grid -->\n      <g stroke=\"#E2E8F0\" stroke-width=\"1\">\n        <line x1=\"60\" y1=\"50\" x2=\"790\" y2=\"50\"\/>\n        <line x1=\"60\" y1=\"90\" x2=\"790\" y2=\"90\"\/>\n        <line x1=\"60\" y1=\"130\" x2=\"790\" y2=\"130\"\/>\n        <line x1=\"60\" y1=\"170\" x2=\"790\" y2=\"170\"\/>\n        <line x1=\"60\" y1=\"210\" x2=\"790\" y2=\"210\"\/>\n        <line x1=\"60\" y1=\"240\" x2=\"790\" y2=\"240\"\/>\n      <\/g>\n\n      <!-- labels (aprox.) -->\n      <g fill=\"#64748B\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">\n        <text x=\"18\" y=\"54\">140<\/text>\n        <text x=\"18\" y=\"94\">100<\/text>\n        <text x=\"22\" y=\"134\">60<\/text>\n        <text x=\"22\" y=\"174\">20<\/text>\n        <text x=\"22\" y=\"214\">0<\/text>\n        <text x=\"20\" y=\"244\">-20<\/text>\n      <\/g>\n\n      <!-- baseline 0 -->\n      <line x1=\"60\" y1=\"210\" x2=\"790\" y2=\"210\" stroke=\"#94A3B8\" stroke-width=\"1.5\" stroke-dasharray=\"4 4\"\/>\n\n      <!-- Study 1 -->\n      <g>\n        <text x=\"150\" y=\"285\" fill=\"#0f172a\" font-size=\"13\" font-family=\"Inter, system-ui, sans-serif\" font-weight=\"800\">Study 1<\/text>\n\n        <!-- Tesamorelin +107 (aprox.) -->\n        <rect x=\"120\" y=\"104\" width=\"70\" height=\"106\" fill=\"rgba(0,200,255,0.25)\" stroke=\"rgba(0,200,255,0.85)\"\/>\n        <text x=\"116\" y=\"96\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Tesa: +107<\/text>\n\n        <!-- Placebo -15 -->\n        <rect x=\"200\" y=\"210\" width=\"70\" height=\"15\" fill=\"rgba(148,163,184,0.35)\" stroke=\"rgba(148,163,184,0.9)\"\/>\n        <text x=\"202\" y=\"202\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Plac: -15<\/text>\n      <\/g>\n\n      <!-- Study 2 -->\n      <g>\n        <text x=\"430\" y=\"285\" fill=\"#0f172a\" font-size=\"13\" font-family=\"Inter, system-ui, sans-serif\" font-weight=\"800\">Study 2<\/text>\n\n        <!-- Tesamorelin +108 -->\n        <rect x=\"400\" y=\"102\" width=\"70\" height=\"108\" fill=\"rgba(0,200,255,0.25)\" stroke=\"rgba(0,200,255,0.85)\"\/>\n        <text x=\"396\" y=\"94\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Tesa: +108<\/text>\n\n        <!-- Placebo +3 (pequeno) -->\n        <rect x=\"480\" y=\"207\" width=\"70\" height=\"3\" fill=\"rgba(148,163,184,0.35)\" stroke=\"rgba(148,163,184,0.9)\"\/>\n        <text x=\"482\" y=\"199\" fill=\"#0f172a\" font-size=\"12\" font-family=\"Inter, system-ui, sans-serif\">Plac: +3<\/text>\n      <\/g>\n\n      <g font-family=\"Inter, system-ui, sans-serif\" font-size=\"12\" fill=\"#334155\">\n        <rect x=\"610\" y=\"36\" width=\"14\" height=\"14\" fill=\"rgba(0,200,255,0.25)\" stroke=\"rgba(0,200,255,0.85)\"\/>\n        <text x=\"632\" y=\"48\">Tesamorelina<\/text>\n        <rect x=\"610\" y=\"58\" width=\"14\" height=\"14\" fill=\"rgba(148,163,184,0.35)\" stroke=\"rgba(148,163,184,0.9)\"\/>\n        <text x=\"632\" y=\"70\">Placebo<\/text>\n      <\/g>\n    <\/svg>\n\n    <div style=\"margin-top:10px; color:#64748b; font-size:13px; line-height:1.6;\">\n      Nota: valores representam <strong>mudan\u00e7a m\u00e9dia<\/strong> em IGF-1 (ng\/mL) a ~26 semanas. A leitura \u00e9 cl\u00ednica: baseline, idade e contexto importam.\n    <\/div>\n  <\/div>\n<\/div>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-timing\">4) Timing: o erro cl\u00e1ssico (meia-vida vs dura\u00e7\u00e3o do efeito)<\/h2>\n\n<p>\n  Aqui \u00e9 onde muita gente se engana. Tr\u00eas coisas diferentes:\n<\/p>\n\n<ul class=\"wp-block-list\">\n  <li><strong>Emivita<\/strong>: quanto tempo a mol\u00e9cula demora a \u201cdescer para metade\u201d no sangue.<\/li>\n  <li><strong>Dura\u00e7\u00e3o do efeito<\/strong>: quanto tempo o corpo continua a responder (GH\/IGF-1 e cascatas a seguir).<\/li>\n  <li><strong>Quando medir<\/strong>: o momento em que faz sentido olhar para um marcador (IGF-1) ou para um resultado (VAT por imagem).<\/li>\n<\/ul>\n\n<div class=\"subject157-note\">\n  <strong>Leitura S157 (curta):<\/strong><br>\n  Se queres estudar timing, documenta o trio: <strong>quando medir<\/strong> (timing), <strong>janela \u00fatil<\/strong> (dura\u00e7\u00e3o do efeito) e <strong>emivita<\/strong> (PK).\n  Se n\u00e3o separares estas coisas, a an\u00e1lise vira ru\u00eddo.\n<\/div>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-safety\">5) Seguran\u00e7a e monitoriza\u00e7\u00e3o: o que \u00e9 \u201cponto de controlo\u201d (sem drama)<\/h2>\n\n<p>\n  O n\u00f3 operacional aqui \u00e9 <strong>IGF-1<\/strong>: ele sobe, e isso \u00e9 um sinal para <strong>monitorizar<\/strong> (n\u00e3o para celebrar \u00e0s cegas).\n  O segundo n\u00f3 \u00e9 contexto: Tesamorelin \u00e9 um medicamento de uso m\u00e9dico em <strong>contexto cl\u00ednico espec\u00edfico<\/strong> e tem contraindica\u00e7\u00f5es\/avisos.\n<\/p>\n\n<ul class=\"wp-block-list\">\n  <li><strong>N\u00e3o \u00e9 \u201cgest\u00e3o de peso\u201d<\/strong>: a pr\u00f3pria documenta\u00e7\u00e3o p\u00fablica descreve efeito \u201cpeso-neutro\u201d.<\/li>\n  <li><strong>Longo prazo<\/strong>: a seguran\u00e7a cardiovascular a longo prazo \u00e9 um tema de cautela na documenta\u00e7\u00e3o.<\/li>\n  <li><strong>Risco metab\u00f3lico<\/strong>: h\u00e1 sinais de aten\u00e7\u00e3o para <strong>intoler\u00e2ncia \u00e0 glicose\/diabetes<\/strong> em alguns dados (monitoriza\u00e7\u00e3o cl\u00ednica).<\/li>\n  <li><strong>Outras cautelas<\/strong>: neoplasia ativa, hipersensibilidade, reten\u00e7\u00e3o de l\u00edquidos, etc. (dom\u00ednio m\u00e9dico).<\/li>\n<\/ul>\n\n<div class=\"subject157-note\">\n  <strong>Nota de Seguran\u00e7a (S157):<\/strong><br>\n  Conte\u00fado educativo. N\u00e3o constitui aconselhamento m\u00e9dico. Para princ\u00edpios de redu\u00e7\u00e3o de risco e enquadramento, consulta a\n  <a href=\"https:\/\/subject157.com\/it\/politica-di-utilizzo-delle-informazioni\/\"><strong>Politica di utilizzo delle informazioni<\/strong><\/a>.\n<\/div>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-framework\">6) Mini-framework S157 (decis\u00e3o r\u00e1pida, sem auto-enganos)<\/h2>\n\n<ol class=\"wp-block-list\">\n  <li><strong>Define o que est\u00e1s a medir<\/strong>: VAT por imagem, composi\u00e7\u00e3o corporal, marcadores no sangue, performance, ou \u201csensa\u00e7\u00e3o\u201d?<\/li>\n  <li><strong>Define o m\u00e9todo<\/strong>: VAT sem CT\/MRI vira \u201chist\u00f3ria\u201d, n\u00e3o dado. M\u00e9todo primeiro, narrativa depois.<\/li>\n  <li><strong>Separa marcador de resultado<\/strong>: IGF-1 \u00e9 um <em>marcador<\/em> (ponto de controlo); VAT \u00e9 um <em>resultado<\/em> medido por imagem.<\/li>\n  <li><strong>Audita o processo<\/strong>: consist\u00eancia de reconstitui\u00e7\u00e3o, registo, e preven\u00e7\u00e3o de erro humano. (<a href=\"https:\/\/subject157.com\/it\/strumenti-di-laboratorio\/\">Strumenti di laboratorio<\/a> - <a href=\"https:\/\/subject157.com\/it\/calcolatrice-u-100\/\">U-100<\/a>)<\/li>\n  <li><strong>Valida o material<\/strong>: sem rastreabilidade e m\u00e9todo anal\u00edtico, \u201c99%\u201d n\u00e3o \u00e9 ci\u00eancia. (<a href=\"https:\/\/subject157.com\/it\/revisore-dei-conti-coa\/\">Revisore COA<\/a>)<\/li>\n  <li><strong>Confirma o contexto<\/strong>: a melhor evid\u00eancia humana vem de um contexto cl\u00ednico espec\u00edfico \u2014 n\u00e3o assumes que \u201ctransfere\u201d para outros cen\u00e1rios sem cautela.<\/li>\n<\/ol>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-related\">Profili di database correlati (6)<\/h2>\n\n<div style=\"display:grid; grid-template-columns:repeat(2, minmax(0, 1fr)); gap:12px; margin-top:10px;\">\n  <div style=\"border:1px solid rgba(15,23,42,0.10); background:#FFFFFF; border-radius:16px; padding:14px;\">\n    <div style=\"font-weight:900; font-size:14px; margin-bottom:6px;\">\n      <a style=\"text-decoration:none;\" href=\"https:\/\/subject157.com\/it\/substances\/tesamorelin\/\">Tesamorelina<\/a>\n    <\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55;\">Perfil central: eixo GH\/IGF-1 + leitura por VAT (imagem) vs marcadores (sangue).<\/div>\n  <\/div>\n\n  <div style=\"border:1px solid rgba(15,23,42,0.10); background:#FFFFFF; border-radius:16px; padding:14px;\">\n    <div style=\"font-weight:900; font-size:14px; margin-bottom:6px;\">\n      <a style=\"text-decoration:none;\" href=\"https:\/\/subject157.com\/it\/substances\/cjc-1295-dac\/\">CJC-1295 (DAC)<\/a>\n    <\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55;\">Bom para comparar \u201csinal mais cont\u00ednuo\u201d vs l\u00f3gica de pulsos e leitura temporal.<\/div>\n  <\/div>\n\n  <div style=\"border:1px solid rgba(15,23,42,0.10); background:#FFFFFF; border-radius:16px; padding:14px;\">\n    <div style=\"font-weight:900; font-size:14px; margin-bottom:6px;\">\n      <a style=\"text-decoration:none;\" href=\"https:\/\/subject157.com\/it\/substances\/cjc-1295-no-dac\/\">CJC-1295 (senza DAC)<\/a>\n    <\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55;\">\u00datil para falar de pulsos (onset\/dura\u00e7\u00e3o) e confus\u00f5es comuns de timing.<\/div>\n  <\/div>\n\n  <div style=\"border:1px solid rgba(15,23,42,0.10); background:#FFFFFF; border-radius:16px; padding:14px;\">\n    <div style=\"font-weight:900; font-size:14px; margin-bottom:6px;\">\n      <a style=\"text-decoration:none;\" href=\"https:\/\/subject157.com\/it\/substances\/ipamorelin\/\">Ipamorelina<\/a>\n    <\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55;\">Compara\u00e7\u00e3o \u00fatil para secretagogos e leitura \u201cmarcador vs resultado\u201d.<\/div>\n  <\/div>\n\n  <div style=\"border:1px solid rgba(15,23,42,0.10); background:#FFFFFF; border-radius:16px; padding:14px;\">\n    <div style=\"font-weight:900; font-size:14px; margin-bottom:6px;\">\n      <a style=\"text-decoration:none;\" href=\"https:\/\/subject157.com\/it\/substances\/ghrp-2\/\">GHRP-2<\/a>\n    <\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55;\">Ajuda a comparar perfis de sinal e discutir toler\u00e2ncia\/dessensibiliza\u00e7\u00e3o (sem romantizar).<\/div>\n  <\/div>\n\n  <div style=\"border:1px solid rgba(15,23,42,0.10); background:#FFFFFF; border-radius:16px; padding:14px;\">\n    <div style=\"font-weight:900; font-size:14px; margin-bottom:6px;\">\n      <a style=\"text-decoration:none;\" href=\"https:\/\/subject157.com\/it\/substances\/ghrp-6\/\">GHRP-6<\/a>\n    <\/div>\n    <div style=\"color:#64748b; font-size:13px; line-height:1.55;\">Outro ponto de compara\u00e7\u00e3o para \u201cforma do sinal\u201d e leitura temporal.<\/div>\n  <\/div>\n<\/div>\n\n<p style=\"margin-top:12px; color:#64748b; font-size:13px; line-height:1.5;\">\n  Dica SEO interna: liga este post tamb\u00e9m ao <a href=\"https:\/\/subject157.com\/it\/database-dei-peptidi\/\"><strong>Database dei peptidi<\/strong><\/a>,\n  ao <a href=\"\/it\/category\/journal\/\"><strong>Giornale di ricerca<\/strong><\/a> e ao <a href=\"https:\/\/subject157.com\/it\/s157-lessico-tattico-glossario\/\"><strong>Lessico<\/strong><\/a>\n  (clusters: GH\/IGF-1, timing, VAT, monitoriza\u00e7\u00e3o).\n<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"s157-refs\">Riferimenti<\/h2>\n\n<div class=\"subject157-references\">\n  <ol>\n    <li>\n      <em>EGRIFTA SV (tesamorelin) \u2014 FDA Label \/ Prescribing Information<\/em> (Revised 02\/2024). Tabelas de estudos cl\u00ednicos (VAT e IGF-1 a ~26 semanas).\n      <br><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022505s018lbl.pdf\" target=\"_blank\" rel=\"noopener\">Abrir PDF (FDA)<\/a>\n    <\/li>\n    <li>\n      Artigos revisados por pares sobre tesamorelin em endpoints de gordura visceral (CT) e biomarcadores (IGF-1) em contexto cl\u00ednico.\n      (Se quiseres, envia 2\u20133 links PubMed\/DOI que preferes como \u201c\u00e2ncoras\u201d e eu troco esta linha por cita\u00e7\u00f5es espec\u00edficas, sem mexer no layout.)\n    <\/li>\n  <\/ol>\n  <p style=\"color:#64748b; font-size:13px; line-height:1.55; margin-top:10px;\">\n    Nota S157: mantive uma \u00e2ncora oficial (FDA) para os n\u00fameros dos gr\u00e1ficos\/tabela. O resto pode ser \u201cancorado\u201d com PubMed\/DOI conforme a tua lista.\n  <\/p>\n<\/div>\n\n<p style=\"color:#64748b; font-size:13px; line-height:1.55; margin-top:16px;\">\n  <strong>Nota de Seguran\u00e7a (S157):<\/strong> Conte\u00fado educativo. N\u00e3o constitui aconselhamento m\u00e9dico.\n  Para princ\u00edpios de redu\u00e7\u00e3o de risco, consulta a <a href=\"https:\/\/subject157.com\/it\/politica-di-utilizzo-delle-informazioni\/\">Politica di utilizzo delle informazioni<\/a>.\n<\/p>\n\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Revisione tecnica degli effetti della tesamorelina sulla riduzione del grasso viscerale, sulle dinamiche GH\/IGF-1 e sulle implicazioni metaboliche basate su studi clinici controllati.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[34,26,22,14,20,28,15,33,37,23,29,32,30,31,35,36,27,38],"class_list":["post-2150","post","type-post","status-publish","format-standard","hentry","category-journal","tag-clinical-data","tag-eixo-gh-igf-1","tag-endocrinologia","tag-gh","tag-ghrh","tag-gordura-visceral","tag-igf-1","tag-lipodistrofia","tag-lipolise","tag-metabolismo","tag-modulacao-endocrina","tag-obesidade-visceral","tag-peptideos-metabolicos","tag-reposicao-hormonal","tag-resistencia-insulinica","tag-saude-metabolica","tag-tesamorelin","tag-vat-reduction"],"acf":[],"_links":{"self":[{"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/posts\/2150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/comments?post=2150"}],"version-history":[{"count":0,"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/posts\/2150\/revisions"}],"wp:attachment":[{"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/media?parent=2150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/categories?post=2150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/subject157.com\/it\/wp-json\/wp\/v2\/tags?post=2150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}